Bacteremic pneumococcal pneumonia: clinical outcomes and preliminary results of inflammatory response

Infection

Volumn 43, Issue 6, 2015, Pages 729-738

  Bordon, J M ^a   Fernandez Botran, R ^b   Wiemken, T L ^b   Peyrani, P ^b   Uriarte, S M ^b   Arnold, F W ^b   Rodriquez Hernandez, L ^b   Rane, M J ^b   Kelley, R R ^b   Binford, L E ^b   Uppatla, S ^b   Cavallazzi, R ^b   Blasi, F ^c   Aliberti, S ^d   Restrepo, M I ^e   Fazeli, S ^a   Mathur, A ^a   Rahmani, M ^a   Ayesu, K ^g   Ramirez, J ^b,f  

^a Providence Hospital Washington DC   (United States)

^b University of Louisville School of Medicine   (United States)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF MILANO BICOCCA   (Italy)

^e SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g ORLANDO HEALTH   (United States)

Author keywords

Biomarkers; Chemokines; Community acquired pneumonia; Cytokines; Inflammatory response; Mortality; Neutrophil functional responses; Outcome; Pneumococcal bacteremia; Pneumonia severity; Streptococcus pneumoniae

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; PROCALCITONIN; TUMOR NECROSIS FACTOR ALPHA; CALCITONIN; CYTOKINE;

ADULT; AGED; ARTICLE; BACTEREMIA; CAUSE OF DEATH; COMMUNITY ACQUIRED PNEUMONIA; FEMALE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; SECONDARY ANALYSIS; STREPTOCOCCUS PNEUMONIA; ADOLESCENT; BLOOD; CHEMISTRY; COMMUNITY ACQUIRED INFECTION; COMPLICATION; ISOLATION AND PURIFICATION; LENGTH OF STAY; MICROBIOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; PLASMA; PROSPECTIVE STUDY; STREPTOCOCCUS PNEUMONIAE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BACTEREMIA; C-REACTIVE PROTEIN; CALCITONIN; COMMUNITY-ACQUIRED INFECTIONS; CYTOKINES; FEMALE; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PLASMA; PNEUMONIA, PNEUMOCOCCAL; PROSPECTIVE STUDIES; STREPTOCOCCUS PNEUMONIAE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84948120695     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-015-0837-z     Document Type: Article

References (29)

1. Heffron R. Pneumonia, with special reference to pneumococcus lobar pneumonia. Cambridge: Harvard University Press; 1939.
2. Moberley S, et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2013;1:CD000422.
3. Griffin MR, et al. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. New Engl J Med. 2013;369:155–63.
4. Nuorti JP, et al. Cigarette smoking and invasive pneumococcal disease. Active bacterial core surveillance team. New Engl J Med. 2000;342:681–9.
5. Musher DM, et al. Bacteremic and nonbacteremic pneumococcal pneumonia. Prospect Study Med. 2000;79:210–21.
6. Song JH, et al. Clinical outcomes of pneumococcal pneumonia caused by antibiotic-resistant strains in asian countries: a study by the Asian network for surveillance of resistant pathogens. Clin Infect Dis Off Publ Infect Dis Soc Am. 2004;38:1570–8.
7. Garcia-Vidal C, et al. Early mortality in patients with community-acquired pneumonia: causes and risk factors. Eur Respir J. 2008;32:733–9.
8. Lin SH, et al. Outcomes of hospitalized patients with bacteraemic and non-bacteraemic community-acquired pneumonia caused by Streptococcus pneumoniae. Epidemiol Infect. 2011;139:1307–16.
9. Fine MJ, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA J Am Med Assoc. 1996;275:134–41.
10. Capelastegui A, et al. Pneumococcal pneumonia: differences according to blood culture results. BMC Pulm Med. 2014;14:128.
11. Kang CI, et al. Risk factors and pathogenic significance of bacteremic pneumonia in adult patients with community-acquired pneumococcal pneumonia. J Infect. 2013;66:34–40.
12. Bordon J, et al. The presence of pneumococcal bacteremia does not influence clinical outcomes in patients with community-acquired pneumonia: results from the Community-Acquired Pneumonia Organization (CAPO) international cohort study. Chest. 2008;133:618–24.
13. Marrie TJ, Low DE, De Carolis E. A comparison of bacteremic pneumococcal pneumonia with nonbacteremic community-acquired pneumonia of any etiology–results from a Canadian multicentre study. Can Respir J J Can Thorac Soc. 2003;10:368–74.
14. Lisboa T, et al. Radiologic progression of pulmonary infiltrates predicts a worse prognosis in severe community-acquired pneumonia than bacteremia. Chest. 2009;135:165–72.
15. Ramirez JA, Bordon J. Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic community-acquired Streptococcus pneumoniae pneumonia. Arch Intern Med. 2001;161:848–50.
16. Borregaard N, Sorensen OE, Theilgaard-Monch K. Neutrophil granules: a library of innate immunity proteins. Trends Immunol. 2007;28:340–5.
17. Sheppard FR, et al. Structural organization of the neutrophil NADPH oxidase: phosphorylation and translocation during priming and activation. J Leukoc Biol. 2005;78:1025–42.
18. Antunes G, et al. Systemic cytokine levels in community-acquired pneumonia and their association with disease severity. Eur Respir J. 2002;20:990–5.
19. Bordon J, et al. Understanding the roles of cytokines and neutrophil activity and neutrophil apoptosis in the protective vs. deleterious inflammatory response in pneumonia. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2013;17:e76–83.
20. Grommes J, Soehnlein O. Contribution of neutrophils to acute lung injury. Mol Med. 2011;17:293–307.
21. Arnold FW, et al. A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am J Respir Crit Care Med. 2007;175:1086–93.
22. Arnold FW, et al. Hospitalization for community-acquired pneumonia: the pneumonia severity index vs. clinical judgment. Chest. 2003;124:121–4.
23. Fine MJ, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. New Engl Jo Med. 1997;336:243–50.
24. Niederman MS, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163:1730–54.
25. Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159:702–6.
26. Lu YJ, et al. Interleukin-17A mediates acquired immunity to pneumococcal colonization. PLoS Pathog. 2008;4:e1000159.
27. Pereira JM, et al. Can we predict pneumococcal bacteremia in patients with severe community-acquired pneumonia? J Crit Care. 2013;28:970–4.
28. Christ-Crain M, et al. Use of B-type natriuretic peptide in the risk stratification of community-acquired pneumonia. J Intern Med. 2008;264:166–76.
29. Chang CL, et al. Biomarkers of cardiac dysfunction and mortality from community-acquired pneumonia in adults. PLoS One. 2013;8:e62612.